Articles Archives - Page 491 of 733

FridayOct 02, 2020 10:41 am

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is “One to Watch”

VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain. The global CNS therapeutics market is estimated to reach $130 billion by 2025 The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care…

ThursdayOct 01, 2020 3:16 pm

Trxade Group, Inc. (NASDAQ: MEDS) Ending Q3 Strong with Increased Investor Exposure

The company’s current independent pharmacy member base represents over 50% of the United States pharmaceutical market within that vertical Actively used in all 50 states with over 11,700 pharmacies in its network, serving around 15 million patients indirectly through these networks of pharmacies Pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) benefited from an increased exposure to potential investors in September, by attending several virtual investor events and conferences, where it was given the opportunity to present its innovative platform and its advantages for pharmacy members. The company started the last month of the third fiscal quarter strong by…

ThursdayOct 01, 2020 2:51 pm

Grey Cloak Tech Inc. (GRCK) is “One to Watch”

Actively executing its growth-by-acquisition strategy, building a portfolio of clinically proven, naturally formulated supplements The BergaMet NA brand is well-positioned for growth throughout North America with its proprietary 47% BPF formulations developed for cardiovascular health, women’s health, immune support, sports performance and recovery UBN subsidiary, with its KETONOMICS(R) proprietary formulation, is well-aligned with Grey Cloak’s corporate strategy to provide better lifestyles through superior health technology. KETONOMICS(R) is medical and scientific research that focuses on the field of brain and physiological metabolism which provides proprietary positions UBN has five unique formulation patents – one issued and four pending – targeting brain…

ThursdayOct 01, 2020 1:53 pm

Pac Roots Cannabis Corp. (CSE: PACR) Adds 250 Acres of Premium Fraser Valley Land to Portfolio

PACR bought nine parcels comprising 250 acres of land in Fraser Valley, British Columbia Share purchase agreement worth $1.5 million cash plus 3 million common shares PACR leverages genetic technology to produce high-yield cannabinoid-specific cultivars that thrive in B.C. climate Pac Roots Cannabis (CSE: PACR), an innovative genetics-based cannabis company based in Canada, has just added 250 acres of premium Fraser Valley land to its portfolio. One of the most intensively farmed areas in Canada, the Fraser Valley generates the most significant farm income of any region in British Columbia. Boasting high-quality soils, a favorable climate, accessible water, and close…

ThursdayOct 01, 2020 1:20 pm

Sugarmade Inc. (SGMD) Garners Accolades by BudCars CEO on Top Cannabis Nationwide Radio Show

BudCars CEO featured guest during “Cannabis Talk 101” show SGMD partnership allowed company to “focus on growth” Walker recognizes Sugarmade’s great accounting, management team The history and future of BudCars Cannabis Delivery Service was spotlighted during a recent “Cannabis Talk 101” episode. BudCars founder and CEO Clinton Walker was a featured guest on the global podcast, which is broadcast on major media networks and top podcast distribution hubs. The impressive potential for BudCars bodes well for Sugarmade (OTCQB: SGMD), which has invested in the burgeoning business. “We are a Northern California premier cannabis delivery [service],” explained Walker, during the program.…

WednesdaySep 30, 2020 3:04 pm

Kaival Brands Innovations Group Inc. (KAVL) Releases Q3 Numbers, Revenues up by 44%

Q3 2020 revenue numbers paint a bright future for KAVL with revenue up by approximately 44% Company closely focused on expanding distribution into large national retailers, convenience chains during Q4 Much of Q3 activity centered around Bidi(TM) Sticks Kaival Brands Innovations Group (OTCQB: KAVL), a company focused on growing and incubating innovative and profitable products into mature, dominant brands, recently released its Q3 financial report. The report showed revenues for KAVL up by approximately 44% compared to Q2 2020. In addition, the report noted that national distribution channels are being established for future growth. “We had an extremely busy and…

WednesdaySep 30, 2020 2:30 pm

Pure Extract Poised to Benefit as Mainstream Society Embraces Functional Mushrooms

Following $1.25 million donation, UC Berkeley launching Center for the Science of Psychedelics Pure Extract Technologies Inc. expanding into functional and medicinal mushroom market Psychedelic compounds increasingly being studied to treat wide range of physical, mental conditions Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell, functional mushroom products For hundreds of years, medicinal mushrooms have been revered among both ancient and modern cultures throughout the world for their nutritional and medicinal qualities. Pure Extract Technologies, a private plant-based Canadian extraction company headquartered in British Columbia, is leveraging the latest in science…

TuesdaySep 29, 2020 1:28 pm

Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments

Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and…

TuesdaySep 29, 2020 12:36 pm

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members,…

TuesdaySep 29, 2020 11:07 am

SRAX Inc. (NASDAQ: SRAX) Acquires LD Micro, Accelerates Adoption of SaaS Data Management Platform

SRAX recently closed acquisition of LD Micro, leading micro-cap information portal LD Micro to become wholly-owned subsidiary of SRAX for 1.6 million in common stock plus $4 million cash Acquisition to accelerate adoption of Sequire, SRAX’s SaaS investment analytics platform Sequire revenue grew 29% year-over-year for Q2 2020, user base doubled to one million users during Q3 2020 SRAX (NASDAQ: SRAX), a data-based financial technology company, recently closed the acquisition of LD Micro, a leading data portal serving the small and micro-cap space. The deal, worth 1,600,000 shares of common stock and $4 million in cash, will make LD Micro…

Site Search

Company Search

Category: Articles